Completed Studies                                                                                                                        updated May 2020

No Study Name/Phase Type Sponsor Population (Gender/Age) Screened Enrolled. (Retention rate) Period
1 Carraguard/Phase III Microbicide Population Council ♀ 18-40 yrs 3604 2402 (86%) 2004-2007
2 FEM PrEP/Phase III Oral Prep FHI360 ♀ 18-35 yrs 1306 764 (87.5%) 2009-2012
3 ACASI/Phase II Behavioural Population Council ♀ 18-40 yrs 390 200 (100%) 2007
4 SBC preparedness /Phase III Mapping FHI360 Community Mapping N/A >1000 (N/A) 2009-2012
5 HSV 2/Phase III HSV2 Treatment Novartis ♀ ≥18 yrs 16 8 (N/A) 2008-2009
6 Diabetic Peripheral Neuropathic/Phase III Observational Pfizer ♂/♀ ≥18 yrs 8 8 (100%) 2011
7 Tyrosur study/Phase III Wound Healing Engelhard Arzneimittel ♂/♀ ≥12 yrs 55 55 (100%) 2012-2013
8 Impetigo/Phase III Impetigo Treatment Galderma Inc ♂/♀ ≥18 yrs 49 49 (100%) 2012-2013
9 PrEP & Risk Compensation/Phase III Behavioural FHI 360 ♀ 18-35 yrs 547 540 (100%) 2012-2013
10 PrEP & Adherence /Phase III Behavioural FHI 360 ♀ 18-35 yrs 229 229 (100%) 2013
11 TESEC 05/Phase III TB Diagnostic Statens Serum Institut ♂/♀ 1-65 yrs 167 164 (98.8%) 2012-2013
12 TESEC 07/Phase II/III TB Diagnostic Statens Serum Institut ♂/♀ 1-65 yrs 66 64 (99%) 2012-2013
13 FACTS 001/Phase III Microbicide CONRAD ♀ 18-30 yrs 685 460 (89%) 2011-2015
14  Group B streptococcus/Phase III Observational Novartis ♀ ≥18 yrs 501 501 (N/A) 2013-2015
15 CE/049/ACT/Phase IV Wound Healing  Smith & Nephew ♂/♀ 0-65 yrs 12 12 (100%) 2015
16 HVTN 100/Phase I/II HIV Vaccine HIV Vaccine Trials Network (HVTN) ♂/♀ 18-35 yrs 127 45 (100%) 2015-2017
17 TRIO MPT Acceptability RTI ♀ 18-35 yrs 170 140 (97.9%) 2015-2016
18 RSV (Season 1)/Phase III RSV Vaccine Novavax ♀ 18-35 yrs 51 36 (100%) 2015-2017
19 RSV (Season 2)/Phase III RSV Vaccine Novavax ♀ 18-35 yrs 171 118 (100%) 2016-2018
20 NC006 (STAND)/Phase III TB Drug therapy TB alliance ♂/♀ ≥18 yrs 45 12 (80%) 2015-2017
21 ASP-CRO-MIC-004/ Bioequivalence Oral Candida Treatment Aspen ♂/♀ ≥18 yrs 10 05 (80%) 2016-2017
22 IMP-Atx/Phase II Impetigo Treatment AntibioTx ♂/♀ 9m – 70 yrs 34 32 (97%) 2018
23 Oral Danarixin/Phase IIa Flu treatment GSK ♂/♀ ≥18 yrs 1 0 2015
24 VISTERA/Phase IIa Flu treatment Pharm-Olam ♂/♀ ≥18 yrs 12 0 2017
25 TB018/Phase III TB Vaccine GSK/IAVI ♂/♀ ≥18 – 50 yrs 1071 467 (N/A) 2014-2019
26 ECHO HIV Risk with Contraception FHI360/University of Washington ♀ 16-35 yrs 1359 864 (N/A) 2015-2019
27 HVTN 108/Phase I/IIa HIV Vaccine HVTN ♂/♀ 18-35 yrs 68 16 (N/A) 2017-2019
28 RSV (Season 3)/Phase III RSV Vaccine Novavax ♀ 18-35 yrs 208 165 2017-2019
29 SCHIELD Behavioural RTI ♀≥18, ♂/♀≥18 N/A 6 FGD’s, 10 IDI’s 2018-2019
30 MENACWY CONJ-069/Phase IIb Meningococcal vaccine GSK ♂/♀10-40 yrs 56 49 2018-2019
31 Bacterial Skin Infection/Phase III Therapeutic MSD ♂/♀3mo-12 yrs 0 0 2019
32 CP40559/Phase III Flu treatment (infants) Roche ♂/♀0-12mo 7 6 2019
33 VICTORIA/Phase III Cardiac Therapeutic MSD ♂/♀≥18 10 6 2018-2020